View in EDS

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Authors: Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University College of Medicine, Seoul, South Korea. Electronic address: mdimop@med.uoa.gr., Schjesvold F; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway., Fu C; The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China., Hartley-Brown MA; Dana-Farber Cancer Institute, Boston, MA, USA., Gomez C; Department of Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK., Reece D; Department of Medical Oncology and Hematology, The Princess Margaret Cancer Centre, Toronto, ON, Canada., Mikala G; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary., Alkharabsheh O; USA Health Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA., Parrish C; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., de Queiroz Crusoé E; D'Or Institute for Research and Education, Salvador, Brazil and Department of Internal Medicine, Federal University of Bahia, Salvador, Brazil., Gálvez K; Hospital Pablo Tobón Uribe, Medellín, Colombia., Idrobo H; Julián Coronel Medical Center, Cali, Colombia., White D; Division of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada., Gupta R; Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA., Lee C; Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia., Liu CJ; Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan., Quach H; Department of Haematology, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia., Wang Y; Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Cerchione C; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy., Forsyth C; Department of Haematology, Gosford Hospital, Gosford, NSW, Australia., Hungria V; Clinica São Germano, São Paulo, Brazil., Kalaskar P; Mumbai Oncocare Centre, Thane, India., Graklanov V; Department of Clinical Hematology, University Hospital Sveti Georgi, Medical University of Plovdiv, Plovdiv, Bulgaria., Ho PJ; Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia., Klaiber-Hakimi M; Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany., Kwong YL; Division of Haematology, Oncology, and Bone Marrow Transplantation, Department of Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China., Louzada M; London Regional Cancer Center, London, ON, Canada., Mazumder A; The Oncology Institute of Hope & Innovation, Glendale, CA, USA., Miles O; Department of Haematology, Musgrove Park Hospital, Taunton, UK., Nagarajan C; Department of Haematology, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore., Prasad SVSS; Department of Hematology and Medical Oncology, Apollo Hospitals, Hyderabad, India., Raab MS; Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Varga G; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary., von der Heyde E; Onkologische Schwerpunktpraxis Dres Ingo Zander und Eyck von der Heyde, Hanover, Germany., Xia Z; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Ochoa PA; Instituto Alexander Fleming, Buenos Aires, Argentina., Oriol A; Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain., Yuda J; Department of Hematology, National Cancer Center Hospital East, Chiba, Japan., Kuroda J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan., Gong J; Bristol Myers Squibb, Princeton, NJ, USA., Zhou Z; Bristol Myers Squibb, Princeton, NJ, USA., Maciag P; Bristol Myers Squibb, Princeton, NJ, USA., Yu B; Bristol Myers Squibb, Princeton, NJ, USA., Rocci A; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland., Koo P; Bristol Myers Squibb, Princeton, NJ, USA., Katz J; Bristol Myers Squibb, Princeton, NJ, USA., Richardson PG; Dana-Farber Cancer Institute, Boston, MA, USA.
Corporate Authors: SUCCESSOR-2 Trial Investigators
Source: Lancet (London, England) [Lancet] 2026 Jun 14. Date of Electronic Publication: 2026 Jun 14.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42289183
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University College of Medicine, Seoul, South Korea. Electronic address: mdimop@med.uoa.gr.<br /><searchLink fieldCode="AU" term="%22Schjesvold+F%22">Schjesvold F</searchLink>; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Fu+C%22">Fu C</searchLink>; The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.<br /><searchLink fieldCode="AU" term="%22Hartley-Brown+MA%22">Hartley-Brown MA</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Gomez+C%22">Gomez C</searchLink>; Department of Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.<br /><searchLink fieldCode="AU" term="%22Reece+D%22">Reece D</searchLink>; Department of Medical Oncology and Hematology, The Princess Margaret Cancer Centre, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Mikala+G%22">Mikala G</searchLink>; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Alkharabsheh+O%22">Alkharabsheh O</searchLink>; USA Health Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.<br /><searchLink fieldCode="AU" term="%22Parrish+C%22">Parrish C</searchLink>; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22de+Queiroz+Crusoé+E%22">de Queiroz Crusoé E</searchLink>; D'Or Institute for Research and Education, Salvador, Brazil and Department of Internal Medicine, Federal University of Bahia, Salvador, Brazil.<br /><searchLink fieldCode="AU" term="%22Gálvez+K%22">Gálvez K</searchLink>; Hospital Pablo Tobón Uribe, Medellín, Colombia.<br /><searchLink fieldCode="AU" term="%22Idrobo+H%22">Idrobo H</searchLink>; Julián Coronel Medical Center, Cali, Colombia.<br /><searchLink fieldCode="AU" term="%22White+D%22">White D</searchLink>; Division of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.<br /><searchLink fieldCode="AU" term="%22Gupta+R%22">Gupta R</searchLink>; Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Lee+C%22">Lee C</searchLink>; Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia.<br /><searchLink fieldCode="AU" term="%22Liu+CJ%22">Liu CJ</searchLink>; Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Quach+H%22">Quach H</searchLink>; Department of Haematology, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Cerchione+C%22">Cerchione C</searchLink>; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.<br /><searchLink fieldCode="AU" term="%22Forsyth+C%22">Forsyth C</searchLink>; Department of Haematology, Gosford Hospital, Gosford, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Hungria+V%22">Hungria V</searchLink>; Clinica São Germano, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Kalaskar+P%22">Kalaskar P</searchLink>; Mumbai Oncocare Centre, Thane, India.<br /><searchLink fieldCode="AU" term="%22Graklanov+V%22">Graklanov V</searchLink>; Department of Clinical Hematology, University Hospital Sveti Georgi, Medical University of Plovdiv, Plovdiv, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Ho+PJ%22">Ho PJ</searchLink>; Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Klaiber-Hakimi+M%22">Klaiber-Hakimi M</searchLink>; Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany.<br /><searchLink fieldCode="AU" term="%22Kwong+YL%22">Kwong YL</searchLink>; Division of Haematology, Oncology, and Bone Marrow Transplantation, Department of Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China.<br /><searchLink fieldCode="AU" term="%22Louzada+M%22">Louzada M</searchLink>; London Regional Cancer Center, London, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Mazumder+A%22">Mazumder A</searchLink>; The Oncology Institute of Hope & Innovation, Glendale, CA, USA.<br /><searchLink fieldCode="AU" term="%22Miles+O%22">Miles O</searchLink>; Department of Haematology, Musgrove Park Hospital, Taunton, UK.<br /><searchLink fieldCode="AU" term="%22Nagarajan+C%22">Nagarajan C</searchLink>; Department of Haematology, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Prasad+SVSS%22">Prasad SVSS</searchLink>; Department of Hematology and Medical Oncology, Apollo Hospitals, Hyderabad, India.<br /><searchLink fieldCode="AU" term="%22Raab+MS%22">Raab MS</searchLink>; Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Varga+G%22">Varga G</searchLink>; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22von+der+Heyde+E%22">von der Heyde E</searchLink>; Onkologische Schwerpunktpraxis Dres Ingo Zander und Eyck von der Heyde, Hanover, Germany.<br /><searchLink fieldCode="AU" term="%22Xia+Z%22">Xia Z</searchLink>; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Ochoa+PA%22">Ochoa PA</searchLink>; Instituto Alexander Fleming, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Oriol+A%22">Oriol A</searchLink>; Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain.<br /><searchLink fieldCode="AU" term="%22Yuda+J%22">Yuda J</searchLink>; Department of Hematology, National Cancer Center Hospital East, Chiba, Japan.<br /><searchLink fieldCode="AU" term="%22Kuroda+J%22">Kuroda J</searchLink>; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.<br /><searchLink fieldCode="AU" term="%22Gong+J%22">Gong J</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Zhou+Z%22">Zhou Z</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Maciag+P%22">Maciag P</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Yu+B%22">Yu B</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Rocci+A%22">Rocci A</searchLink>; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.<br /><searchLink fieldCode="AU" term="%22Koo+P%22">Koo P</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Katz+J%22">Katz J</searchLink>; Bristol Myers Squibb, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22SUCCESSOR-2+Trial+Investigators%22">SUCCESSOR-2 Trial Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2026 Jun 14. <i>Date of Electronic Publication: </i>2026 Jun 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42289183
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(26)01088-3
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Schjesvold F
      – PersonEntity:
          Name:
            NameFull: Fu C
      – PersonEntity:
          Name:
            NameFull: Hartley-Brown MA
      – PersonEntity:
          Name:
            NameFull: Gomez C
      – PersonEntity:
          Name:
            NameFull: Reece D
      – PersonEntity:
          Name:
            NameFull: Mikala G
      – PersonEntity:
          Name:
            NameFull: Alkharabsheh O
      – PersonEntity:
          Name:
            NameFull: Parrish C
      – PersonEntity:
          Name:
            NameFull: de Queiroz Crusoé E
      – PersonEntity:
          Name:
            NameFull: Gálvez K
      – PersonEntity:
          Name:
            NameFull: Idrobo H
      – PersonEntity:
          Name:
            NameFull: White D
      – PersonEntity:
          Name:
            NameFull: Gupta R
      – PersonEntity:
          Name:
            NameFull: Lee C
      – PersonEntity:
          Name:
            NameFull: Liu CJ
      – PersonEntity:
          Name:
            NameFull: Quach H
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Cerchione C
      – PersonEntity:
          Name:
            NameFull: Forsyth C
      – PersonEntity:
          Name:
            NameFull: Hungria V
      – PersonEntity:
          Name:
            NameFull: Kalaskar P
      – PersonEntity:
          Name:
            NameFull: Graklanov V
      – PersonEntity:
          Name:
            NameFull: Ho PJ
      – PersonEntity:
          Name:
            NameFull: Klaiber-Hakimi M
      – PersonEntity:
          Name:
            NameFull: Kwong YL
      – PersonEntity:
          Name:
            NameFull: Louzada M
      – PersonEntity:
          Name:
            NameFull: Mazumder A
      – PersonEntity:
          Name:
            NameFull: Miles O
      – PersonEntity:
          Name:
            NameFull: Nagarajan C
      – PersonEntity:
          Name:
            NameFull: Prasad SVSS
      – PersonEntity:
          Name:
            NameFull: Raab MS
      – PersonEntity:
          Name:
            NameFull: Varga G
      – PersonEntity:
          Name:
            NameFull: von der Heyde E
      – PersonEntity:
          Name:
            NameFull: Xia Z
      – PersonEntity:
          Name:
            NameFull: Ochoa PA
      – PersonEntity:
          Name:
            NameFull: Oriol A
      – PersonEntity:
          Name:
            NameFull: Yuda J
      – PersonEntity:
          Name:
            NameFull: Kuroda J
      – PersonEntity:
          Name:
            NameFull: Gong J
      – PersonEntity:
          Name:
            NameFull: Zhou Z
      – PersonEntity:
          Name:
            NameFull: Maciag P
      – PersonEntity:
          Name:
            NameFull: Yu B
      – PersonEntity:
          Name:
            NameFull: Rocci A
      – PersonEntity:
          Name:
            NameFull: Koo P
      – PersonEntity:
          Name:
            NameFull: Katz J
      – PersonEntity:
          Name:
            NameFull: Richardson PG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 06
              Text: 2026 Jun 14
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1